Meeting News

NLA Scientific Sessions focus on new methods to manage lipids

James A. Underberg, MS, MD, FACP, FACPM, FNLA
James A. Underberg

Experts will discuss why lipids are an important risk factor for CVD and ways health care providers can treat these patients at this year’s National Lipid Association Scientific Sessions.

The 4-day meeting will take place Thursday, April 26, to Sunday, April 29, at the JW Marriott in Las Vegas and will feature intensive sessions on topics such as diet, lipoprotein(a), familial hypercholesterolemia and updates in research.

Lipids as risk factors

“Not only are abnormal lipids important, but even when people have other risk factors such as hypertension and diabetes, improving their lipids seems to have an important impact,” James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, clinical assistant professor of the department of medicine at NYU Langone Health, director of Bellevue Hospital Lipid Clinic in New York and president and committee co-chair of the NLA, told Cardiology Today.

The target audience of the NLA Scientific Sessions goes beyond internal medicine practitioners, lipid specialist and cardiologists. Other specialists that can benefit from these sessions include nurse practitioners, pharmacists, nurses, physician associates, registered dietitians, exercise physiologists, OB-GYNs and surgeons who treat patients with heart disease, Underberg said.

“We have a fairly wide net,” he said in an interview. “The breadth of attendees at our conferences and our membership is a diverse one from a practice perspective.”

Penny Kris-Etherton

On Friday, the W. Virgil Brown Distinguished Achievement Award Lecture will be given by Penny Kris-Etherton, PhD, RDN, CLS, FNLA, distinguished professor of nutrition at Pennsylvania State University.

Robert Giugliano
Robert P. Giugliano
There is also a session on Friday focused on gender and unique underserved issues, including transgender medicine, menopause and premature ovarian insufficiency.

“This is quite a diverse type of topic, but one that is particularly relevant to cardiology practice and this space of cardiovascular medicine and lipidology,” Underberg told Cardiology Today.

Experts will discuss recent clinical trials on PCSK9 inhibitors like ODYSSEY Outcomes and FOURIER on Friday. Information will be presented by Vera A. Bittner, MD, MSPH, FNLA, professor in the department of medicine at the University of Alabama at Birmingham, Robert P. Giugliano, MD, SM, associate professor at Harvard Medical School, and Pamela B. Morris, MD, FNLA, associate professor at Medical University of South Carolina in Charleston.

Gene editing

State-of-the-art developments in lipid science, including gene editing with clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9), will also be presented by Kiran Musunuru, MD, PhD, MPH, associate professor of cardiovascular medicine and genetics at the Perelman School of Medicine at the University of Pennsylvania.

Kiran Musunuru

The sessions will also include poster presentations with award winners.

“This has continued to grow every year and brings in young members to the organization,” Underberg said. “Highlighting the achievements of those young members and encouraging their development toward leadership is another important feature of our meeting.”

These sessions have a personal aspect that is sometimes not seen in larger meetings, he said.

“There’s an important collegial aspect of our meetings,” Underberg told Cardiology Today. “Many of our members are often the only ones doing lipidology at their institution, so the ability to connect with likeminded individuals who are interested and focused on the same thing for a couple of days together can be reinvigorating in the perspective of both clinical academic and research practice.”

Cardiology Today will provide coverage from the NLA Scientific Sessions, including reports on the sessions, onsite video interviews and much more. For more information on the NLA agenda and registration, visit www.lipid.org. – by Darlene Dobkowski

For more information:

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, can be reached at james.underberg@nyumc.org.

Disclosure: Underberg reports he has consulted for Akcea Therapeutics, Amgen, Regeneron and Sanofi.

James A. Underberg, MS, MD, FACP, FACPM, FNLA
James A. Underberg

Experts will discuss why lipids are an important risk factor for CVD and ways health care providers can treat these patients at this year’s National Lipid Association Scientific Sessions.

The 4-day meeting will take place Thursday, April 26, to Sunday, April 29, at the JW Marriott in Las Vegas and will feature intensive sessions on topics such as diet, lipoprotein(a), familial hypercholesterolemia and updates in research.

Lipids as risk factors

“Not only are abnormal lipids important, but even when people have other risk factors such as hypertension and diabetes, improving their lipids seems to have an important impact,” James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, clinical assistant professor of the department of medicine at NYU Langone Health, director of Bellevue Hospital Lipid Clinic in New York and president and committee co-chair of the NLA, told Cardiology Today.

The target audience of the NLA Scientific Sessions goes beyond internal medicine practitioners, lipid specialist and cardiologists. Other specialists that can benefit from these sessions include nurse practitioners, pharmacists, nurses, physician associates, registered dietitians, exercise physiologists, OB-GYNs and surgeons who treat patients with heart disease, Underberg said.

“We have a fairly wide net,” he said in an interview. “The breadth of attendees at our conferences and our membership is a diverse one from a practice perspective.”

Penny Kris-Etherton

On Friday, the W. Virgil Brown Distinguished Achievement Award Lecture will be given by Penny Kris-Etherton, PhD, RDN, CLS, FNLA, distinguished professor of nutrition at Pennsylvania State University.

PAGE BREAK

Robert Giugliano
Robert P. Giugliano
There is also a session on Friday focused on gender and unique underserved issues, including transgender medicine, menopause and premature ovarian insufficiency.

“This is quite a diverse type of topic, but one that is particularly relevant to cardiology practice and this space of cardiovascular medicine and lipidology,” Underberg told Cardiology Today.

Experts will discuss recent clinical trials on PCSK9 inhibitors like ODYSSEY Outcomes and FOURIER on Friday. Information will be presented by Vera A. Bittner, MD, MSPH, FNLA, professor in the department of medicine at the University of Alabama at Birmingham, Robert P. Giugliano, MD, SM, associate professor at Harvard Medical School, and Pamela B. Morris, MD, FNLA, associate professor at Medical University of South Carolina in Charleston.

Gene editing

State-of-the-art developments in lipid science, including gene editing with clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9), will also be presented by Kiran Musunuru, MD, PhD, MPH, associate professor of cardiovascular medicine and genetics at the Perelman School of Medicine at the University of Pennsylvania.

Kiran Musunuru

The sessions will also include poster presentations with award winners.

“This has continued to grow every year and brings in young members to the organization,” Underberg said. “Highlighting the achievements of those young members and encouraging their development toward leadership is another important feature of our meeting.”

These sessions have a personal aspect that is sometimes not seen in larger meetings, he said.

“There’s an important collegial aspect of our meetings,” Underberg told Cardiology Today. “Many of our members are often the only ones doing lipidology at their institution, so the ability to connect with likeminded individuals who are interested and focused on the same thing for a couple of days together can be reinvigorating in the perspective of both clinical academic and research practice.”

Cardiology Today will provide coverage from the NLA Scientific Sessions, including reports on the sessions, onsite video interviews and much more. For more information on the NLA agenda and registration, visit www.lipid.org. – by Darlene Dobkowski

For more information:

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, can be reached at james.underberg@nyumc.org.

Disclosure: Underberg reports he has consulted for Akcea Therapeutics, Amgen, Regeneron and Sanofi.

    See more from National Lipid Association Scientific Sessions